Is Sangani Hospital overvalued or undervalued?

As of 29 August 2025, Sangani Hospital's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE ratio of 35.59, an EV to EBITDA of 29.71, and a ROCE of 12.91%.
In comparison to its peers, Sangani Hospital's valuation appears favorable; for instance, Apollo Hospitals has a significantly higher PE ratio of 69.47 and an EV to EBITDA of 35.76, while Max Healthcare is even more expensive with a PE of 92.6. Despite a recent decline in stock price, Sangani Hospital has outperformed the Sensex over the past year, with a return of 59.29% compared to the Sensex's -2.88%. This reinforces the view that the stock is currently undervalued relative to its growth potential and peer performance.